{"name":"ContraVir Pharmaceuticals, Inc.","slug":"contravir-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":445512,"netIncome":-8277850,"cash":13922972,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CMX157","genericName":"CMX157","slug":"cmx157","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CMX157","genericName":"CMX157","slug":"cmx157","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQR0E2YVpQT0RjWDJZM2NuNVh0YUxWQ1ROWE5VYXB5MEkyUUQ0ZWhTVHlaUU5hbDAtZGtGQ0gyd1dQaVNmT2xOSFFrX3U0TlZ6UFYzQ19qdDFPTTYwM0tXc0I0TFVVMTk4ZVpFOE9VSEF6ZWJGbTlYaXdLSEdZQUNxVDZDdHJyN3lFUW9KcndSeE1XaVU?oc=5","date":"2025-07-03","type":"pipeline","source":"University of Alberta","summary":"Journey to the Order of Canada | Pharmacy - University of Alberta","headline":"Journey to the Order of Canada | Pharmacy","sentiment":"neutral"},{"date":"2025-06-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-06-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-06-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-05-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-05-19","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-05-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPdkVIZEkwQlBUbk9GMUV3MXBHU3RURmNjMUx4T01TTmR2RVI5R1hsX2t2WXBFNXpVWl9tcXUxVkdHQjRCZFhMRzk3WDlibEs4Y3U4enVIS2hwWG1EdzduV3N1RUE0dlJMZE5rei1qLVFYb3V0UW5GdVpYOVFtM1hIZFZYeExmc3IwUGhGTDUydm1rQQ?oc=5","date":"2024-06-28","type":"trial","source":"Life Science Leader","summary":"Cash Needed For Phase 3 Celiac Drug Development - Life Science Leader","headline":"Cash Needed For Phase 3 Celiac Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNUGxuS3BGNWpUbERPYWhnQ3BnbE50OFdlT2RvaXFrOW1fZHNnb2xmRUtUS1VoNHRNRVFDbkNzNFFLZzVJMDdNVXJLNzFRT2VrY21FTEV6YU1RdGFWT2YtdVMyT0JpWWNoWlE2dUdCWGNwcXNqMm5aX2U1c2J1ZHJyazFkTndNX2NPaGJGa2huRG15bF9HSEpVRXRVSUJuQWs?oc=5","date":"2024-04-25","type":"pipeline","source":"Life Science Leader","summary":"Reviva Pharma's Novel Funding Approach In Schizophrenia - Life Science Leader","headline":"Reviva Pharma's Novel Funding Approach In Schizophrenia","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":0,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"},{"value":0,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":445512,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-8277850,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":13922972,"cashHistory":[],"totalAssets":3069952,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}